Specialized Eye Diseases Hospital For Active Treatment-Varna EOOD — Clinical Trial Site

8 Registered trials

2 Currently recruiting

Organisation

Specialized Eye Diseases Hospital For Active Treatment-Varna EOOD

Location

Varna, Bulgaria

Identifier

ORG-100046639

Address

Ulitsa Doyran 15, 9002, Bulgaria

Departments

1000002: Diagnostic Consultative Department
100003 : Department for eye diseases
Department of Eye Diseases
Department of opthalmology diseases
Eye disease
NAP

Clinical trials at this site (8)

Search interface

A Study to Compare the Effectiveness and Safety of T1695 (0.1% Tacrolimus) Versus Ciclosporin in Participants With Moderate to Severe Vernal… Pending

2025-521567-12-00 Vernal Keratoconjunctivitis (VKC) 4
LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of … Recruiting

2024-513356-15-00 Acquired Blepharoptosis 5 2024-12-30
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema Recruiting

2025-522231-34-00 Diabetic Macular Edema 5 2026-03-31
Extension Study to Evaluate the Long-Term Outcomes of Paediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe… Ended

2024-513231-24-00 Retinopathy of prematurity (ROP) 5 2022-03-22
A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended

2022-502174-16-00 Macular edema secondary to retinal vein occlusion 5 2023-09-13
Extension study to evaluate the long-term outcomes of subjects in study 20090 Ended

2023-504207-89-00 Retinopathy of prematurity 5 2020-03-27
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension Ended

2022-502380-37-00 Open-Angle Glaucoma 5 2019-08-02
A Clinical Trial to compare Efficacy, Safety, Tolerability of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneratio… Ended

2023-509206-29-00 Neovascular age-related macular degeneration (nAMD) 5